CDXS

Codexis, Inc.
CAPPED RATING

Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.

Codexis, Inc. (CDXS) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D+). The rating has held at C for 14 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.1
EV / EBITDA -6.7
Rev Growth YoY -2.7%
Gross Margin 24.3%
Price Return 3M -37.5%
Price Return 12M -40.8%
Catalyst Signal 0.00
Market Cap $109.5M
TTM Revenue $77.7M
Price / Sales 1.4
ROE -69.4%

Historical Factor Score Progression

Held C for 14 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.0) C (2.3) C- (2.1) D+ (1.7) C+ (2.6) C (2.3)
2026-11-04 B- (3.0) C (2.3) C- (2.1) D+ (1.7) C+ (2.7) C (2.4)
2026-10-28 B- (3.0) C (2.3) C- (2.1) D+ (1.7) C+ (2.7) C (2.3)
2026-10-21 B- (3.0) C (2.3) C- (2.1) D (1.2) C+ (2.6) C (2.2)
2026-10-14 B- (3.0) C (2.3) C- (2.1) D (1.3) C+ (2.6) C (2.3)
Page 1 of 8
…